Chemo-Refractory Gastric Cancer Treated With Toripalimab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety, Efficacy and Tumor Mutational Burden as a Biomarker of Overall Survival Benefit in Chemo-Refractory Gastric Cancer Treated With Toripalimab, a PD1 Antibody in Phase Ib/II Clinical Trial NCT02915432
Ann. Oncol 2019 Jun 24;[EPub Ahead of Print], F Wang, XL Wei, FH Wang, N Xu, L Shen, GH Dai, XL Yuan, Y Chen, SJ Yang, JH Shi, XC Hu, XY Lin, QY Zhang, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH XuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.